<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anakinra: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anakinra: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Anakinra: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10941" href="/d/html/10941.html" rel="external">see "Anakinra: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13251" href="/d/html/13251.html" rel="external">see "Anakinra: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135465"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kineret</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865938"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Kineret</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F135484"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antirheumatic, Disease Modifying;</li>
<li>
                        Interleukin-1 Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F135468"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cdaa6e2-2b4e-4195-93ca-238c40cd2164">Behçet disease, mucocutaneous, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Behçet disease, mucocutaneous, refractory (adjunctive agent) (off-label use): SUBQ: </b>Initial: 100 mg once daily in combination with other immunosuppressants (eg, corticosteroids); if ulcers persist, may increase to 200 mg once daily after 1 month and further increase to 300 mg once daily after 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28335798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28335798'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0891d0ae-7e24-405b-8311-22bb89c363db">Calcium pyrophosphate crystal deposition disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium pyrophosphate crystal deposition disease (ie, pseudogout) (alternative agent) (off-label use):</b>
<b>SUBQ</b>: 100 mg once daily. Usual duration of therapy for acute attacks is ~3 to 9 days; however, some patients may require long-term treatment to control symptoms after the acute attack (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25922564','lexi-content-ref-32359034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25922564','lexi-content-ref-32359034'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="894e2a7e-3fff-4cb6-8ddb-f11aa30fb548">COVID-19, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, hospitalized patients (off-label use): Note: </b>For patients requiring supplemental oxygen who are at risk for progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-34480127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-34480127'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ: </b>100 mg once daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-34480127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-34480127'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46bffb95-c08f-4726-850b-dc9ea584498a">Cytokine storm syndromes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytokine storm syndromes (adjunctive agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The IV route is preferred for doses &gt;2 mg/kg/day or &gt;100 mg/day, or in patients with platelets &lt;20 × 10<sup>9</sup>/L, presence of significant skin edema, or neurological symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32373790']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32373790'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>2 mg/kg/<b>hour</b> as a continuous infusion for up to 72 hours, <b>or</b> 2 to 10 mg/kg/<b>day</b> in 2 to 4 divided doses; use in combination with corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605776'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ: </b>2 to 10 mg/kg/<b>day</b> in 2 to 4 divided doses; use in combination with corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605776'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8eab757c-af8e-49ca-9fcb-f56ae226aab1">Deficiency of interleukin-1 receptor antagonist</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deficiency of interleukin-1 receptor antagonist: SUBQ:</b> Initial: 1 to 2 mg/kg daily; adjust dose in 0.5 to 1 mg/kg increments as needed to a maximum of 8 mg/kg daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="38fc3d56-4103-4ab4-b784-435867dde0d9">Neonatal-onset multisystem inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neonatal-onset multisystem inflammatory disease:</b>
<b>SUBQ</b>
<b>:</b> Initial: 1 to 2 mg/kg daily in 1 to 2 divided doses; adjust dose in 0.5 to 1 mg/kg increments as needed; usual maintenance dose: 3 to 4 mg/kg daily (maximum: 8 mg/kg daily). <b>Note:</b> Once-daily administration is preferred; however, the dose may also be divided and administered twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd2834ea-9693-41ae-856f-f7f4864e097c">Familial Mediterranean fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial Mediterranean fever (off-label use):</b>
<b>SUBQ</b>
<b>:</b> 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27860460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27860460'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95db442d-efd8-4b89-a10a-1e5c87357c02">Gout, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment (acute flares) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for patients in whom first-line therapies are ineffective, contraindicated, or not tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934','lexi-content-ref-27457514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934','lexi-content-ref-27457514'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 100 mg once daily until symptom improvement; usual duration: 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27457514','lexi-content-ref-23650178','lexi-content-ref-30602035','lexi-content-ref-33605029','lexi-content-ref-17352828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27457514','lexi-content-ref-23650178','lexi-content-ref-30602035','lexi-content-ref-33605029','lexi-content-ref-17352828'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8e428b43-282f-46ae-a92b-bf555a945f48">Pericarditis, recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pericarditis, recurrent (off-label use):</b>
<b>SUBQ:</b> 100 mg once daily. Usual duration of therapy is ~6 months followed by a taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27825009','lexi-content-ref-21029567','lexi-content-ref-31610707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27825009','lexi-content-ref-21029567','lexi-content-ref-31610707'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b>
<b>SUBQ</b>
<b>:</b> 100 mg once daily (administer at approximately the same time each day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6408b952-3837-492c-83f5-84d78a145712">Still disease, adult onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Still disease, adult onset (alternative agent) (off-label use): SUBQ: </b>Initial: 100 mg once daily usually in combination with other immunosuppressants (eg, corticosteroids). In patients with incomplete response, may increase to 200 mg/day in 1 or 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28659802','lexi-content-ref-35481241','lexi-content-ref-26426623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28659802','lexi-content-ref-35481241','lexi-content-ref-26426623'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991756"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute or end-stage renal disease:</p>
<p style="text-indent:-2em;margin-left:4em;">COVID-19, hospitalized patients: Consider administering 100 mg every other day for a total of 5 doses over 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Other indications: Consider administering the prescribed dose every other day.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable (&lt;2.5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous ambulatory peritoneal dialysis (CAPD): Not dialyzable (&lt;2.5%)</p></div>
<div class="block doha drugH1Div" id="F50988892"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F135469"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F16330957"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13251" href="/d/html/13251.html" rel="external">see "Anakinra: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8eab757c-af8e-49ca-9fcb-f56ae226aab1">Deficiency of interleukin-1 receptor antagonist</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deficiency of interleukin-1 receptor antagonist (DIRA):</b> Infants, Children, and Adolescents: SubQ: Initial: 1 to 2 mg/kg/dose once daily; may titrate in 0.5 to 1 mg/kg increments up to a maximum dose of 8 mg/kg/dose to achieve control of active inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19494218','lexi-content-ref-19494219','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19494218','lexi-content-ref-19494219','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c629917-9ec4-4b87-af31-43ed572d5b31">Familial Mediterranean Fever; colchicine-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial Mediterranean Fever; colchicine-resistant:</b> Limited data available: Children ≥2 years and Adolescents: SubQ: 1 to 2 mg/kg/dose once daily; dose, frequency, and duration of therapy were adjusted as needed based on clinical response; reported range: 1 to 5 mg/kg/dose; maximum dose: 100 mg/dose. One center has reported transitioning to less frequent doses (every other day) in patients who remain attack-free for 6 months; on-demand treatment during times of specific triggers (eg, menstrual cycle) has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26001859','lexi-content-ref-32558310','lexi-content-ref-32306038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26001859','lexi-content-ref-32558310','lexi-content-ref-32306038'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (JIA):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Systemic-onset JIA (SOJIA): Children and Adolescents: SubQ: Initial: 1 to 2 mg/kg/dose once daily; maximum initial dose: 100 mg; if no response, may titrate typically at 2-week intervals by doubling dose up to 4 mg/kg/dose once daily; maximum dose: 200 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22290637','lexi-content-ref-18438814','lexi-content-ref-22083619','lexi-content-ref-Irigoyen.2006','lexi-content-ref-17947302','lexi-content-ref-21280009','lexi-content-ref-21173013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22290637','lexi-content-ref-18438814','lexi-content-ref-22083619','lexi-content-ref-Irigoyen.2006','lexi-content-ref-17947302','lexi-content-ref-21280009','lexi-content-ref-21173013'])">Ref</a></span>). Anakinra was shown efficacious as first-line monotherapy in single-center, prospective cohort trial including 42 pediatric patients (median age: 7.1 years); dosing was initiated at 2 mg/kg/dose if after 3 days fever remained the dose was increased to 4 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30848528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30848528'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Polyarticular course JIA: Children ≥2 years and Adolescents: SubQ: 1 mg/kg once daily; maximum dose: 100 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18766426','lexi-content-ref-16303102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18766426','lexi-content-ref-16303102'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2d8e162-9093-4b87-b65b-1ea65140f237">Kawasaki disease, refractory to IVIG</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kawasaki disease, refractory to IVIG:</b> Limited data available; optimal dose, timing, and duration of anakinra therapy has not been defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months weighing ≥5 kg to &lt;8 months weighing &lt;10 kg: SubQ: Initial: 4 mg/kg/dose once daily; if fever persisted or recurred 24 hours after previous anakinra dose, the dose was increased in 2 mg/kg increments; maximum daily dose: 8 mg/kg/<b>day</b>; anakinra was continued for 14 days total of anakinra therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32779863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32779863'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥8 months, Children, and Adolescents weighing ≥10 kg: SubQ: Initial: 2 mg/kg/dose once daily; if fever persisted or recurred 24 hours after previous anakinra dose, the dose was increased in 2 mg/kg increments; maximum daily dose: 6 mg/kg/<b>day</b>;<b></b>anakinra was continued for 14 days total of anakinra therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32779863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32779863'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on the largest trial (KAWAKINRA study), a phase 2, open-labeled, multicenter trial evaluating 16 patients (median age: 31 months; range: 3 to 83 months), which initiated anakinra for recurrent or persistent fever 48 hours after the last dose of IVIG; after the last escalation of dose, 87.5% in the per protocol group were afebrile and 75% in the intent-to-treat group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32779863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32779863'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Reported dosing from smaller case series and reports: 1 to 10 mg/kg/day in 1 to 2 divided doses; in several reports, doses were initiated at the low to mid-range (1 to 6 mg/kg) and titrated based on response and subsequently tapered to discontinued therapy; the duration of therapy variable, up to 180 days has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445','lexi-content-ref-32073531','lexi-content-ref-22689319','lexi-content-ref-32885390','lexi-content-ref-32457855','lexi-content-ref-28390409','lexi-content-ref-25045337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445','lexi-content-ref-32073531','lexi-content-ref-22689319','lexi-content-ref-32885390','lexi-content-ref-32457855','lexi-content-ref-28390409','lexi-content-ref-25045337'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2409ba83-3fab-48ac-bd75-41b00b70b569">Multisystem inflammatory syndrome in children associated with SARS-CoV-2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2:</b> Very limited data available: <b>Note:</b> Recommended for intensification therapy in patients who do not improve within 24 hours of initial MIS-C therapy (ie, immune globulin and methylprednisolone); do not use in combination with infliximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-NIH.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, SUBQ: 5 to 10 mg/kg/day in 1 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021','lexi-content-ref-35118829','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021','lexi-content-ref-35118829','lexi-content-ref-NIH.1'])">Ref</a></span>); duration varies and is dependent upon clinical course; tapering over at least 2 to 3 weeks has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021','lexi-content-ref-35118829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021','lexi-content-ref-35118829'])">Ref</a></span>). <b>Note:</b> While poorly documented, the IV route may be preferred for MIS-C (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="263dac27-7ee9-4d13-9dea-662a4981f422">Neonatal-onset multisystem inflammatory disease or chronic infantile neurological, cutaneous, and articular syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neonatal-onset multisystem inflammatory disease (NOMID) or chronic infantile neurological, cutaneous, and articular syndrome (CINCA) [cryopyrin-associated periodic syndromes (CAPS)]:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: SubQ: Initial: 1 to 2 mg/kg/day in 1 to 2 divided doses; adjust dose in 0.5 to 1 mg/kg increments as needed to control inflammation; usual maintenance dose: 3 to 4 mg/kg/day; maximum daily dose: 8 mg/kg/<b>day</b>. <b>Note:</b> Once-daily administration is preferred; however, the dose may also be divided and administered twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b> Adolescents ≥18 years: SubQ: 100 mg once daily; administer at approximately the same time each day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064857"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Deficiency of interleukin-1 receptor antagonist</i>
<i> (DIRA), neonatal-onset multisystem inflammatory disease (NOMID) (cryopyrin-associated periodic syndromes [CAPS]; chronic infantile neurological, cutaneous, and articular syndrome [CINCA]):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Decrease frequency of administration to every other day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rheumatoid arthritis:</i> Adolescents ≥18 years: Consider 100 mg every other day.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease: &lt;2.5% of the dose is removed by hemodialysis or CAPD:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Deficiency of interleukin-1 receptor antagonist (DIRA), neonatal-onset multisystem inflammatory disease (NOMID) (cryopyrin-associated periodic syndromes [CAPS]; chronic infantile neurological, cutaneous, and articular syndrome [CINCA]):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Decrease frequency of administration to every other day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rheumatoid arthritis:</i> Adolescents ≥18 years: 100 mg every other day.</p></div>
<div class="block dohp drugH1Div" id="F51064858"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F135440"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19 infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">The following adverse drug reactions and incidences are derived from the FDA issued emergency use authorization (EUA [FDA 2022]). Adverse reactions reported for adults.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%: Hepatic: Increased gamma-glutamyl transferase (14%), increased serum transferase (31%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hyperkalemia (9%), hypernatremia (10%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Constipation (9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Leukopenia (4%), neutropenia (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Anxiety (8%), hypothermia (7%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Acute kidney injury (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis/neonatal-onset multisystem inflammatory disease (NOMAD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">The following adverse drug reactions and incidences are derived from product labeling. Adverse reactions reported for adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Vomiting (infants, children, and adolescents: 14%)</p>
<p style="text-indent:-2em;margin-left:6em;">Immunologic: Antibody development (49%; neutralizing: 2%; no correlation between antibody development and adverse effects)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Infection (39%; serious infection: 2% to 3%; including cellulitis, pneumonia, and bone and/or joint infections)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection site reaction (adults: 71%; infants, children, and adolescents: 16%; including bruising at injection site, erythema at injection site, inflammation at injection site, pain at injection site)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Headache (infants, children, adolescents, and adults: 12% to 14%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (infants, children, and adolescents: 12%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Nasopharyngitis (infants, children, and adolescents: 12%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (infants, children, and adolescents: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Malignant melanoma</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Malignant lymphoma, malignant neoplasm</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hypercholesterolemia</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Gastroenteritis</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Opportunistic infection</p>
<p style="text-indent:-2em;margin-left:6em;">Otic: Otitis media</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Sinusitis, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (noninfectious), increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F135453"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to <i>E. coli</i>-derived proteins, anakinra, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F135438"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported. Patients with deficiency of interleukin-1 receptor antagonist (DIRA) may have an increased risk of allergic reactions, especially within the first few weeks of initiating therapy; monitor closely. Discontinue use if severe hypersensitivity occurs; medications for the treatment of hypersensitivity reactions should be available for immediate use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Associated with an increased risk of serious infections in rheumatoid arthritis studies. Anakinra should not be initiated in patients with an active infection. If a patient receiving anakinra for rheumatoid arthritis develops a serious infection, therapy should be discontinued; if a patient receiving anakinra for neonatal-onset multisystem inflammatory disease (NOMID) or DIRA develops a serious infection, the risk of a disease flare should be weighed against the risks associated with continued treatment. Safety and efficacy have not been evaluated in immunosuppressed patients or patients with chronic infections; the impact on active or chronic infections has not been determined. Immunosuppressive therapy (including anakinra) may lead to reactivation of tuberculosis (TB) infection (latent TB) or other atypical or opportunistic infections; test patients for TB infection prior to initiation, and treat TB infection prior to use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection site reactions: Injection site reactions commonly occur (within first 4 weeks of therapy) and are generally mild with a duration of 14 to 28 days. Patients who do not experience an injection site reaction within the first 4 weeks of therapy are not likely to experience one; the incidence of injection site reactions may be lower in patients on concomitant oral corticosteroids (Kaiser 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: May affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neutropenia: A decrease in neutrophil count may occur during treatment. Assess neutrophil count at baseline, monthly for 3 months, then every 3 months for up to 1 year. In a limited number of patients with NOMID, neutropenia resolved over time with continued anakinra administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Underlying pulmonary disease: Patients with underlying pulmonary disease (eg, asthma) may have increased risk of serious infection (Fleischmann 2003).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor necrosis factor inhibitors: Anakinra should not be initiated in patients receiving tumor necrosis factor–blocking agents (eg, etanercept) due to increased risk of serious infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use caution due to the potential higher risk for infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold anakinra for at least 1 day prior to surgery to reduce infection risk (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy; live vaccines should not be given concurrently. There are no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878328"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Reactivation of TB has been reported in pediatric patients receiving biologic response modifiers (infliximab and etanercept); prior to therapy, patients with no TB risk factors should be screened for latent TB infection (LTBI) with an age appropriate test (ie, &lt;5 years of age: tuberculin skin test, and ≥5 years of age: IGRA [interferon gamma release assay]); if any TB risk factors are present or symptoms, both LTBI screening tests should be performed (AAP [Davies 2016])</p></div>
<div class="block foc drugH1Div" id="F135448"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kineret: 100 mg/0.67 mL (0.67 mL) [contains disodium edta, polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F135434"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F135455"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Kineret Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/0.67 mL (per 0.67 mL): $236.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865939"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kineret: 100 mg/0.67 mL (0.67 mL) [contains disodium edta, polysorbate 80]</p></div>
<div class="block accres drugH1Div" id="F53867150"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">For patient self-administration, product may be obtained via the Kineret On Track program. Further information is available at https://www.kineretrx.com/hcp/kineret-on-track.php or 1-866-547-0644.</p></div>
<div class="block adm drugH1Div" id="F135450"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Allow solution to warm to room temperature prior to use (30 minutes). Inject into outer area of upper arms, abdomen (do not use within 2 inches of belly button), front of middle thighs, or upper outer buttocks. Rotate injection sites; do not administer into tender, swollen, bruised, red, or hard skin or skin with scars or stretch marks. If dose is separated into 2 injections, a new syringe should be used for each dose. After proper training, patients may self-inject, or the patient's caregiver may administer anakinra.</p></div>
<div class="block admp drugH1Div" id="F52612241"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: Rotate injection sites; inject into outer area of upper arms, abdomen (do not use within 2 inches of belly button), front of middle thighs, or upper outer buttocks; injection should be given at least 1 inch away from previous injection site; do not administer into tender, swollen, bruised, red, or hard skin or skin with scars or stretch marks. Allow solution to warm to room temperature prior to use (30 minutes). Do not shake. Provided in single-use, preservative-free syringes with 27-gauge needles; discard any unused portion.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Very limited data available: Administer over 1 to 3 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27080929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27080929'])">Ref</a></span>) or over 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34187503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34187503'])">Ref</a></span>). Longer infusion times (up to 3 hours) have been described in pharmacokinetic studies in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1420996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1420996'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F135449"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Deficiency of interleukin-1 receptor antagonist:</b> Treatment of deficiency of interleukin-1 receptor antagonist.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neonatal-onset multisystem inflammatory disease:</b> Treatment of neonatal-onset multisystem inflammatory disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b> Reduction in signs and symptoms and slowing the progression of structural damage of moderately to severely active rheumatoid arthritis in patients ≥18 years of age in whom 1 or more disease-modifying antirheumatic drugs have failed.</p></div>
<div class="block off-label drugH1Div" id="F25816343"><span class="drugH1">Use: Off-Label: Adult</span><p>Behçet disease, mucocutaneous, refractory; Calcium pyrophosphate crystal deposition disease (ie, pseudogout); COVID-19, hospitalized patients; Cytokine storm syndromes; Familial Mediterranean fever; Gout, treatment (acute flares); Pericarditis, recurrent; Still disease, adult onset</p></div>
<div class="block mst drugH1Div" id="F135491"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anakinra may be confused with amikacin, Ampyra</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kineret may be confused with Amikin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298752"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F135442"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-TNF Agents: May enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May enhance the immunosuppressive effect of Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canakinumab: Interleukin-1 Receptor Antagonist may enhance the adverse/toxic effect of Canakinumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54119846"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Based on limited data, use of anakinra may be continued through conception in patients with rheumatic and musculoskeletal diseases who are planning to become pregnant and not able to use alternative therapies; use should be discontinued once pregnancy is confirmed. Conception should be planned during a period of quiescent/low disease activity (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Based on limited data, use of anakinra may be continued in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F135456"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data related to the use of anakinra during pregnancy are limited (Berger 2009; Brien 2021; Chang 2014; Dernoncourt 2023; Duman 2019; Ghalandari 2022; İlgen 2017; Ozdogan 2019; Youngstein 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Until additional data are available, anakinra is not currently recommended for the treatment of rheumatic and musculoskeletal diseases during pregnancy. Anakinra should be discontinued once pregnancy is confirmed (ACR [Sammaritano 2020]). Agents other than anakinra are currently recommended for the treatment of familial Mediterranean fever during pregnancy (EULAR [Ozen 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes in patients with rheumatoid arthritis is ongoing. Patients exposed to anakinra during pregnancy may contact the Organization of Teratology Information Services (OTIS), Rheumatoid Arthritis and Pregnancy Study at 1-877-311-8972.</p></div>
<div class="block brc drugH1Div" id="F135457"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">It is not known if anakinra is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Adverse events have not been observed in breastfeeding infants following maternal use of anakinra (Berger 2009; Chang 2014; Duman 2019; Youngstein 2017). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Concentrations of anakinra are expected to be limited in breast milk due to large molecular weight. Also, because anakinra is unlikely to be absorbed by the infant gastrointestinal tract following exposure via breast milk, treatment with anakinra may be initiated in breastfeeding patients with rheumatic and musculoskeletal diseases (ACR [Sammaritano 2020]).</p></div>
<div class="block mop drugH1Div" id="F135446"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential (baseline, then monthly for 3 months, then every 3 months for a period up to 1 year); TB test (baseline); serum creatinine; signs/symptoms of infection; injection site reactions.</p></div>
<div class="block pha drugH1Div" id="F135437"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Antagonist of the interleukin-1 (IL-1) receptor. Endogenous IL-1 is induced by inflammatory stimuli and mediates a variety of immunological responses, including degradation of cartilage (loss of proteoglycans) and stimulation of bone resorption.</p></div>
<div class="block phk drugH1Div" id="F135452"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: 95%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 4 to 6 hours; Severe renal impairment (CrCl &lt;30 mL/minute): ~7 hours; ESRD: 9.7 hours (Yang 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: SUBQ: 3 to 7 hours</p></div>
<div class="block phksp drugH1Div" id="F51220437"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mean plasma clearance in patients with mild (CrCl 50 to 80 mL/minute), moderate (CrCl 30 to 49 mL/minute), severe (CrCl &lt;30 mL/minute), and end-stage renal disease (ESRD) was decreased by 16%, 50%, 70%, and 75%, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F135458"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Anakinra amgen | Kineret</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Kineret</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26320112">
<a name="26320112"></a>Adler Y, Charron P, Imazio M, et al; European Society of Cardiology (ESC). 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/26320112/pubmed" id="26320112" target="_blank">26320112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19494218">
<a name="19494218"></a>Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. <i>N Engl J Med</i>. 2009;360(23):2426-2437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/19494218/pubmed" id="19494218" target="_blank">19494218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). What is the case definition of multisystem inflammatory syndrome in children (MIS-C)? Updated November 15, 2021. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25922564">
<a name="25922564"></a>Aouba A, Deshayes S, Frenzel L, et al. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature. <i>Mediators Inflamm</i>. 2015;2015:792173. doi:10.1155/2015/792173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/25922564/pubmed" id="25922564" target="_blank">25922564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36233667">
<a name="36233667"></a>Baverez C, Grall M, Gerfaud-Valentin M, et al. Anakinra for the treatment of hemophagocytic lymphohistiocytosis: 21 cases.<i> J Clin Med</i>. 2022;11(19):5799. doi:10.3390/jcm11195799<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/36233667/pubmed" id="36233667" target="_blank">36233667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27860460">
<a name="27860460"></a>Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheumatol</i>. 2017;69(4):854‐862. doi:10.1002/art.39995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27860460/pubmed" id="27860460" target="_blank">27860460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19822718">
<a name="19822718"></a>Berger CT, Recher M, Steiner U, Hauser TM. A patient's wish: anakinra in pregnancy [published correction appears in <i>Ann Rheum Dis</i>. 2010;69(1):28]. <i>Ann Rheum Dis</i>. 2009;68(11):1794‐1795. doi:10.1136/ard.2008.105833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/19822718/pubmed" id="19822718" target="_blank">19822718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073531">
<a name="32073531"></a>Blonz G, Lacroix S, Benbrik N, et al. Severe late-onset Kawasaki disease successfully treated with anakinra. <i>J Clin Rheumatol</i>. 2020;26(2):e42-e43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32073531/pubmed" id="32073531" target="_blank">32073531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35011965">
<a name="35011965"></a>Brien ME, Gaudreault V, Hughes K, Hayes DJL, Heazell AEP, Girard S. A systematic review of the safety of blocking the IL-1 system in human pregnancy. <i>J Clin Med</i>. 2021;11(1):225. doi:10.3390/jcm11010225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/35011965/pubmed" id="35011965" target="_blank">35011965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27825009">
<a name="27825009"></a>Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. <i>JAMA</i>. 2016;316(18):1906-1912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27825009/pubmed" id="27825009" target="_blank">27825009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16440135">
<a name="16440135"></a>Callejas JL, Oliver J, Martín J, et al. Anakinra in Mutation-Negative CINCA Syndrome. <i>Clin Rheumatol</i>. 2007;26(4):576-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/16440135/pubmed" id="16440135" target="_blank">16440135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21029567">
<a name="21029567"></a>Cantarini L, Lucherini OM, Cimaz R, Galeazzi M. Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. <i>Clin Exp Rheumatol</i>. 2010;28(5):802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21029567/pubmed" id="21029567" target="_blank">21029567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24305945">
<a name="24305945"></a>Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet's disease: a case series. <i>Clin Rheumatol.</i> 2015;34(7):1293-1301. doi:10.1007/s10067-013-2443-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/24305945/pubmed" id="24305945" target="_blank">24305945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25223501">
<a name="25223501"></a>Chang Z, Spong CY, Jesus AA, et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). <i>Arthritis Rheumatol</i>. 2014;66(11):3227-3232. doi:10.1002/art.38811<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/25223501/pubmed" id="25223501" target="_blank">25223501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32359034">
<a name="32359034"></a>Cipolletta E, Di Matteo A, Scanu A, et al. Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review. <i>Clin Exp Rheumatol.</i> 2020;38(5):1001-1007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32359034/pubmed" id="32359034" target="_blank">32359034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11920396">
<a name="11920396"></a>Cohen S, Hurd E, Cush J, et al. Treatment of Rheumatoid Arthritis With Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Combination With Methotrexate: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis Rheum</i>. 2002;46(3):614-624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/11920396/pubmed" id="11920396" target="_blank">11920396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22689319">
<a name="22689319"></a>Cohen S, Tacke CE, Straver B, Meijer N, Kuipers IM, Kuijpers TW. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. <i>Ann Rheum Dis</i>. 2012;71(12):2059-2061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/22689319/pubmed" id="22689319" target="_blank">22689319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28659802">
<a name="28659802"></a>Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still's disease: a multicentre retrospective observational study. <i>Front Pharmacol.</i> 2017;8:369. doi:10.3389/fphar.2017.00369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/28659802/pubmed" id="28659802" target="_blank">28659802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432853">
<a name="27432853"></a>Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27432853/pubmed" id="27432853" target="_blank">27432853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36401769">
<a name="36401769"></a>Dernoncourt A, Liabeuf S, Bennis Y, et al. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization Pharmacovigilance Database (VigiBase®). <i>BioDrugs</i>. 2023;37(1):73-87. doi:10.1007/s40259-022-00564-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/36401769/pubmed" id="36401769" target="_blank">36401769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30442822">
<a name="30442822"></a>Desmarais J, Chu CQ. Utility of anakinra in acute crystalline diseases: a retrospective study comparing a university hospital with a veterans affairs medical center. <i>J Rheumatol.</i> 2019;46(7):748-750. doi:10.3899/jrheum.180393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/30442822/pubmed" id="30442822" target="_blank">30442822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22290637">
<a name="22290637"></a>Dewitt EM, Kimura Y, Beukelman T, et al; Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(7):1001-1010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/22290637/pubmed" id="22290637" target="_blank">22290637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22832289">
<a name="22832289"></a>Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. <i>J Clin Rheumatol</i>. 2012;18(6):310-311. doi:10.1097/RHU.0b013e31826149a2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/22832289/pubmed" id="22832289" target="_blank">22832289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34218418">
<a name="34218418"></a>Doaré E, Robin F, Racapé H, et al. Features and outcomes of microcrystalline arthritis treated by biologics: a retrospective study. <i>Rheumatol Ther</i>. 2021;8(3):1241-1253. doi:10.1007/s40744-021-00335-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/34218418/pubmed" id="34218418" target="_blank">34218418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Duman.2019">
<a name="Duman.2019"></a>Duman NC, Goren MZ, Karaalp A. Anakinra use during pregnancy and lactation: A case report. <i>Reprod Toxicol. </i>2019;88:139-40. doi:10.1016/j.reprotox.2019.05.029</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26001859">
<a name="26001859"></a>Eroglu FK, Beşbaş N, Topaloglu R, Ozen S. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. <i>Rheumatol Int</i>. 2015;35(10):1733-1737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/26001859/pubmed" id="26001859" target="_blank">26001859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32885390">
<a name="32885390"></a>Ferrara G, Giani T, Caparello MC, Farella C, Gamalero L, Cimaz R. Anakinra for treatment-resistant Kawasaki disease: evidence from a literature review. <i>Paediatr Drugs</i>. 2020;22(6):645-652.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32885390/pubmed" id="32885390" target="_blank">32885390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32391934">
<a name="32391934"></a>FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. <i>Arthritis Care Res (Hoboken)</i>. 2020;72(6):744-760. doi:10.1002/acr.24180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32391934/pubmed" id="32391934" target="_blank">32391934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12687534">
<a name="12687534"></a>Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist (r-metHuIL-1ra), in Patients With Rheumatoid Arthritis: A Large, International, Multicenter, Placebo-Controlled Trial. <i>Arthritis Rheum.</i> 2003;48(4):927-934. doi:10.1002/art.10870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/12687534/pubmed" id="12687534" target="_blank">12687534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16396977">
<a name="16396977"></a>Fleischmann RM, Tesser J, Schiff MH, et al. Safety of Extended Treatment With Anakinra in Patients With Rheumatoid Arthritis. <i>Ann Rheum Dis</i>. 2006,65(8):1006-1012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/16396977/pubmed" id="16396977" target="_blank">16396977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35481241">
<a name="35481241"></a>Galozzi P, Bindoli S, Doria A, Sfriso P. Progress in biological therapies for adult-onset Still's disease. <i>Biologics</i>. 2022;16:21-34. doi:10.2147/BTT.S290329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/35481241/pubmed" id="35481241" target="_blank">35481241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32457855">
<a name="32457855"></a>Gambacorta A, Buonsenso D, De Rosa G, et al. Resolution of giant coronary aneurisms in a child with refractory Kawasaki disease treated with anakinra. <i>Front Pediatr</i>. 2020;8:195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32457855/pubmed" id="32457855" target="_blank">32457855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18438814">
<a name="18438814"></a>Gattorno M, Piccini A, Lasigliè D, et al. The Pattern of Response to Anti-Interleukin-1 Treatment Distinguishes Two Subsets of Patients With Systemic-Onset Juvenile Idiopathic Arthritis. <i>Arthritis Rheum</i>. 2008;58(5):1505-1515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/18438814/pubmed" id="18438814" target="_blank">18438814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15146410">
<a name="15146410"></a>Genovese MC, Cohen S, Moreland L, et al. Combination Therapy With Etanercept and Anakinra in the Treatment of Patients With Rheumatoid Arthritis Who Have Been Treated Unsuccessfully With Methotrexate. <i>Arthritis Rheum</i>. 2004;50(5):1412-1519.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/15146410/pubmed" id="15146410" target="_blank">15146410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24646465">
<a name="24646465"></a>Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. <i>Medicine (Baltimore).</i> 2014;93(2):91-99. doi:10.1097/MD.0000000000000021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/24646465/pubmed" id="24646465" target="_blank">24646465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35894810">
<a name="35894810"></a>Ghalandari N, Crijns HJMJ, Bergman JEH, Dolhain RJEM, van Puijenbroek EP, Hazes JMW. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: a retrospective comparative study in EudraVigilance. <i>Br J Clin Pharmacol.</i> 2022;88(12):5378-5388. doi:10.1111/bcp.15471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/35894810/pubmed" id="35894810" target="_blank">35894810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23650178">
<a name="23650178"></a>Ghosh P, Cho M, Rawat G, Simkin PA, et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. <i>Arthritis Care Res</i> (<i>Hoboken</i>). 2013;65(8):1381-1384. doi:10.1002/acr.21989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/23650178/pubmed" id="23650178" target="_blank">23650178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23225779">
<a name="23225779"></a>Giampietro C, Ridene M, Lequerre T, et al; CRI (Club Rhumatismes et Inflammation). Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. <i>Arthritis Care Res (Hoboken)</i>. 2013;65(5):822-826. doi:10.1002/acr.21901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/23225779/pubmed" id="23225779" target="_blank">23225779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16899778">
<a name="16899778"></a>Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1Beta Inhibition. <i>N Engl J Med</i>. 2006;355(6):581-592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/16899778/pubmed" id="16899778" target="_blank">16899778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken).</i> 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1420996">
<a name="1420996"></a>Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. <i>Cytokine</i>. 1992;4(5):353-360. doi:10.1016/1043-4666(92)90078-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/1420996/pubmed" id="1420996" target="_blank">1420996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28335798">
<a name="28335798"></a>Grayson PC, Yazici Y, Merideth M, et al. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.<i> Arthritis Res Ther.</i> 2017;19(1):69. doi:10.1186/s13075-017-1222-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/28335798/pubmed" id="28335798" target="_blank">28335798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22083619">
<a name="22083619"></a>Hedrich CM, Bruck N, Fiebig B, Gahr M. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). <i>Rheumatol Int</i>. 2012;32(11):3525-3530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/22083619/pubmed" id="22083619" target="_blank">22083619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35118829">
<a name="35118829"></a>Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology (ACR) clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. <i>Arthritis Rheumatol</i>. Published online February 3, 2022. doi:10.1002/art.42062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/35118829/pubmed" id="35118829" target="_blank">35118829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605776">
<a name="34605776"></a>Hines MR, von Bahr Greenwood T, Beutel G, et al. Consensus-based guidelines for the recognition, diagnosis, and management of hemophagocytic lymphohistiocytosis in critically ill children and adults. <i>Crit Care Med.</i> 2022;50(5):860-872. doi:10.1097/CCM.0000000000005361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/34605776/pubmed" id="34605776" target="_blank">34605776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28293457">
<a name="28293457"></a>İlgen U, Küçükşahin O. Anakinra use during pregnancy: Report of a case with Familial Mediterranean Fever and infertility. <i>Eur J Rheumatol</i>. 2017;4(1):66-67. doi: 10.5152/eurjrheum.2017.16075.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/28293457/pubmed" id="28293457" target="_blank">28293457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010097">
<a name="23010097"></a>Iliou C, Papagoras C, Tsifetaki N, Voulgari PV, Drosos AA. Adult-onset Still's disease: clinical, serological and therapeutic considerations. <i>Clin Exp Rheumatol.</i> 2013;31(1):47-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/23010097/pubmed" id="23010097" target="_blank">23010097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18766426">
<a name="18766426"></a>Ilowite N, Porras O, Reiff A, et al. Anakinra in the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis: Safety and Preliminary Efficacy Results of a Randomized Multicenter Study. <i>Clin Rheumatol</i>. 2009;28(2):129-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/18766426/pubmed" id="18766426" target="_blank">18766426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31610707">
<a name="31610707"></a>Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (International Registry of Anakinra for Pericarditis) study. <i>Eur J Prev Cardiol</i>. 2020;27(9):956-964. doi:10.1177/2047487319879534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/31610707/pubmed" id="31610707" target="_blank">31610707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Irigoyen.2006">
<a name="Irigoyen.2006"></a>Irigoyen P, Olson J, Horn C, et al. Treatment of Systemic Onset Juvenile Idiopathic Arthritis With Anakinra. <i>Ped Rheumatol Online J</i>. 2006;4(2):123-134.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30602035">
<a name="30602035"></a>Janssen CA, Oude Voshaar MAH, Vonkeman HE, et al. Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. <i>Rheumatology (Oxford)</i>. Published online January 2, 2019. doi:10.1093/rheumatology/key402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/30602035/pubmed" id="30602035" target="_blank">30602035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21881988">
<a name="21881988"></a>Kaiser C, Knight A, Nordström D, et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations.<i> Rheumatol Int.</i> 2012;32(2):295-299. doi:10.1007/s00296-011-2096-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21881988/pubmed" id="21881988" target="_blank">21881988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17891446">
<a name="17891446"></a>Kashiwagi Y, Kawashima H, Nishimata S, et al. Extreme Efficiency of Anti-Interleukin 1 Agent (Anakinra) in a Japanese Case of CINCA Syndrome. <i>Clin Rheumatol</i>. 2008;27(2):277-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/17891446/pubmed" id="17891446" target="_blank">17891446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kineret.1">
<a name="Kineret.1"></a>Kineret (anakinra) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32779863">
<a name="32779863"></a>Koné-Paut I, Tellier S, Belot A, et al. Phase II open label study of anakinra in intravenous immunoglobulin-resistant Kawasaki disease. <i>Arthritis Rheumatol</i>. 2021;73(1):151-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32779863/pubmed" id="32779863" target="_blank">32779863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27328763">
<a name="27328763"></a>Kucuksahin O, Yildizgoren MT, Ilgen U, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial Mediterranean fever. <i>Mod Rheumatol</i>. 2017;27(2):350-355. doi:10.1080/14397595.2016.1194510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27328763/pubmed" id="27328763" target="_blank">27328763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32558310">
<a name="32558310"></a>Kurt T, Aydın F, Nilüfer Tekgöz P, Sezer M, Uncu N, Çelikel Acar B. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience. <i>Int J Rheum Dis</i>. 2020;23(7):977-981.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32558310/pubmed" id="32558310" target="_blank">32558310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34480127">
<a name="34480127"></a>Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nat Med</i>. 2021;27(10):1752-1760. doi:10.1038/s41591-021-01499-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/34480127/pubmed" id="34480127" target="_blank">34480127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25165036">
<a name="25165036"></a>Lazaros G, Vasileiou P, Koutsianas C, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. <i>Ann Rheum Dis</i>. 2014;73(12):2215-2217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/25165036/pubmed" id="25165036" target="_blank">25165036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947302">
<a name="17947302"></a>Lequerré T, Quartier P, Rosellini D, et al; Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. <i>Ann Rheum Dis</i>. 2008;67(3):302-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/17947302/pubmed" id="17947302" target="_blank">17947302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15818707">
<a name="15818707"></a>Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 Blockade by Anakinra Improves Clinical Symptoms in Patients With Neonatal-Onset Multisystem Inflammatory Disease. <i>Arthritis Rheum</i>. 2005;52(4):1283-1286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/15818707/pubmed" id="15818707" target="_blank">15818707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34144604">
<a name="34144604"></a>Marko L, Shemer A, Lidar M, et al. Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients.<i> Rheumatology (Oxford)</i>. 2021;60(6):2878-2883. doi:10.1093/rheumatology/keaa728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/34144604/pubmed" id="34144604" target="_blank">34144604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449034">
<a name="16449034"></a>Matsubayashi T, Sugiura H, Arai T, et al. Anakinra Therapy for CINCA Syndrome With a Novel Mutation in Exon 4 of the CIAS1 Gene. <i>Acta Paediatr</i>. 2006;95(2):246-249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/16449034/pubmed" id="16449034" target="_blank">16449034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356445">
<a name="28356445"></a>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/28356445/pubmed" id="28356445" target="_blank">28356445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32373790">
<a name="32373790"></a>Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome.<i> Lancet Rheumatol.</i> 2020;2(6):e358-e367. doi:10.1016/S2665-9913(20)30096-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32373790/pubmed" id="32373790" target="_blank">32373790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in children (MIS-C) (with discussion on multisystem inflammatory syndrome in adults [MIS-A]). <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/</a>. Updated February 24, 2022. Accessed March 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20107032">
<a name="20107032"></a>Naumann L, Feist E, Natusch A, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. <i>Ann Rheum Dis</i>. 2010;69(2):466-467. doi:10.1136/ard.2009.108068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/20107032/pubmed" id="20107032" target="_blank">20107032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35948764">
<a name="35948764"></a>Naymagon L. Anakinra for the treatment of adult secondary HLH: a retrospective experience. <i>Int J Hematol</i>. 2022;116(6):947-955. doi:10.1007/s12185-022-03430-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/35948764/pubmed" id="35948764" target="_blank">35948764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20039428">
<a name="20039428"></a>Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. <i>Arthritis and Rheumatism</i>. 2010;62(1): 258-267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/20039428/pubmed" id="20039428" target="_blank">20039428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21280009">
<a name="21280009"></a>Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. <i>Arthritis Rheum</i>. 2011;63(2):545-555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21280009/pubmed" id="21280009" target="_blank">21280009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18321945">
<a name="18321945"></a>Ohlsson V, Baildam E, Foster H, et al. Anakinra Treatment for Systemic Onset Juvenile Idiopathic Arthritis (SOJIA). <i>Rheumatology (Oxford).</i> 2008;47(4):555-556.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/18321945/pubmed" id="18321945" target="_blank">18321945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26426623">
<a name="26426623"></a>Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review. <i>Medicine (Baltimore).</i> 2015;94(39):e1554. doi:10.1097/MD.0000000000001554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/26426623/pubmed" id="26426623" target="_blank">26426623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24432362">
<a name="24432362"></a>Ottaviani S, Moltó A, Ea HK, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. <i>Arthritis Res Ther</i>. 2013;15(5):R123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/24432362/pubmed" id="24432362" target="_blank">24432362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26802180">
<a name="26802180"></a>Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. <i>Ann Rheum Dis</i>. 2016;75(4):644-651. doi:10.1136/annrheumdis-2015-208690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/26802180/pubmed" id="26802180" target="_blank">26802180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30686512">
<a name="30686512"></a>Ozdogan H, Ugurlu S. Familial mediterranean fever. <i>Presse Med</i>. 2019;48(1 Pt 2):e61‐e76. doi:10.1016/j.lpm.2018.08.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/30686512/pubmed" id="30686512" target="_blank">30686512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15851489">
<a name="15851489"></a>Pascual V, Allantaz F, Arce E, et al. Role of Interleukin-1 (IL-1) in the Pathogenesis of Systemic Onset Juvenile Idiopathic Arthritis and Clinical Response to IL-1 Blockade. <i>J Exp Med.</i> 2005; 201(9):1479-1486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/15851489/pubmed" id="15851489" target="_blank">15851489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28097903">
<a name="28097903"></a>Pecher AC, Igney-Oertel A, Kanz L, Henes J. Treatment of familial Mediterranean fever with anakinra in patients unresponsive to colchicine. <i>Scand J Rheumatol</i>. 2017:1-3. doi:10.1080/03009742.2016.1245780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/28097903/pubmed" id="28097903" target="_blank">28097903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34187503">
<a name="34187503"></a>Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S. Intravenous administration of anakinra in children with macrophage activation syndrome. <i>Pediatr Rheumatol Online J</i>. 2021;19(1):98. doi:10.1186/s12969-021-00585-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/34187503/pubmed" id="34187503" target="_blank">34187503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19116906">
<a name="19116906"></a>Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? <i>Arthritis Rheum</i>. 2009;60(1):264-268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/19116906/pubmed" id="19116906" target="_blank">19116906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21173013">
<a name="21173013"></a>Quartier P, Allantaz, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). <i>Ann Rheum Di</i>s. 2011;70(5):747-754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21173013/pubmed" id="21173013" target="_blank">21173013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19494219">
<a name="19494219"></a>Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. <i>N Engl J Med</i>. 2009;360(23):2438-2444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/19494219/pubmed" id="19494219" target="_blank">19494219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16303102">
<a name="16303102"></a>Reiff A. The Use of Anakinra in Juvenile Arthritis. <i>Curr Rheumatol Rep</i>. 2005;7(6):434-440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/16303102/pubmed" id="16303102" target="_blank">16303102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457514">
<a name="27457514"></a>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27457514/pubmed" id="27457514" target="_blank">27457514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21385548">
<a name="21385548"></a>Riera E, Olivé A, Narváez J, et al. Adult onset Still's disease: review of 41 cases. <i>Clin Exp Rheumatol</i>. 2011;29(2):331-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21385548/pubmed" id="21385548" target="_blank">21385548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21240490">
<a name="21240490"></a>Rigante D, Leone A, Marrocco R, et al. Long-Term Response After 6-Year Treatment With Anakinra and Onset of Focal Bone Erosion in Neonatal-Onset Multisystem Inflammatory Disease (NOMID/CINCA). <i>Rheumatol Int</i>. 2011;31(12):1661-1664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21240490/pubmed" id="21240490" target="_blank">21240490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16525848">
<a name="16525848"></a>Rigante D, Ansuini V, Caldarelli M, et al. Hydrocephalus in CINCA Syndrome Treated With Anakinra. <i>Childs Nerv Syst</i>. 2006;22(4):334-337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/16525848/pubmed" id="16525848" target="_blank">16525848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24092554">
<a name="24092554"></a>Ringold S, Weiss PF, Beukelman T, et al; American College of Rheumatology. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Rheum</i>. 2013;65(10):2499-2512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/24092554/pubmed" id="24092554" target="_blank">24092554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33605029">
<a name="33605029"></a>Saag KG, Khanna PP, Keenan RT, et al. A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. <i>Arthritis Rheumatol</i>. 2021;73(8):1533-1542. doi:10.1002/art.41699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/33605029/pubmed" id="33605029" target="_blank">33605029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18512708">
<a name="18512708"></a>Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis Rheum</i>. 2008;59(6):762-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/18512708/pubmed" id="18512708" target="_blank">18512708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32306038">
<a name="32306038"></a>Sag E, Akal F, Atalay E, et al. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. <i>Rheumatology (Oxford)</i>. 2020;59(11):3324-3329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32306038/pubmed" id="32306038" target="_blank">32306038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28390409">
<a name="28390409"></a>Sánchez-Manubens J, Gelman A, Franch N, et al. A child with resistant Kawasaki disease successfully treated with anakinra: a case report. <i>BMC Pediatr</i>. 2017;17(1):102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/28390409/pubmed" id="28390409" target="_blank">28390409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25045337">
<a name="25045337"></a>Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. <i>Pediatr Rheumatol Online J</i>. 2014;12:26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/25045337/pubmed" id="25045337" target="_blank">25045337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22294344">
<a name="22294344"></a>Sibley CH, Plass N, Snow J, et al. Sustained Response and Prevention of Damage Progression in Patients With Neonatal-Onset Multisystem Inflammatory Disease Treated With Anakinra: A Cohort Study to Determine Three- and Five-Year Outcomes. <i>Arthritis Rheum</i>. 2012;64(7):2375-2386.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/22294344/pubmed" id="22294344" target="_blank">22294344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17352828">
<a name="17352828"></a>So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. <i>Arthritis Res Ther</i>. 2007;9(2):R28. doi:10.1186/ar2143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/17352828/pubmed" id="17352828" target="_blank">17352828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30848528">
<a name="30848528"></a>Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. <i>Arthritis Rheumatol</i>. 2019;71(7):1163-1173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/30848528/pubmed" id="30848528" target="_blank">30848528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30145636">
<a name="30145636"></a>Thomas M, Forien M, Palazzo E, Dieudé P, Ottaviani S. Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases. <i>Clin Rheumatol.</i> 2019;38(2):425-430. doi:10.1007/s10067-018-4272-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/30145636/pubmed" id="30145636" target="_blank">30145636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27080929">
<a name="27080929"></a>Tremoulet AH, Jain S, Kim S, et al. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). <i>Contemp Clin Trials</i>. 2016;48:70-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27080929/pubmed" id="27080929" target="_blank">27080929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on COVID-19 Treatment Guidelines. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://covid19treatmentguidelines.nih.gov" target="_blank">https://covid19treatmentguidelines.nih.gov</a>. Updated September 1, 2020. Accessed September 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine: Emergency Use Authorization (EUA) for Kineret. <a href="https://www.fda.gov/media/163075/download" target="_blank">https://www.fda.gov/media/163075/download</a>. Accessed November 8, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27110096">
<a name="27110096"></a>van der Hilst JCH, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. <i>Biologics</i>. 2016;10:75-80. doi:10.2147/BTT.S102954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27110096/pubmed" id="27110096" target="_blank">27110096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30755262">
<a name="30755262"></a>Vercruysse F, Barnetche T, Lazaro E, et al. Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy. <i>Arthritis Res Ther.</i> 2019;21(1):53. doi:10.1186/s13075-019-1838-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/30755262/pubmed" id="30755262" target="_blank">30755262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32154255">
<a name="32154255"></a>Vitale A, Cavalli G, Ruscitti P, et al. Comparison of early vs. delayed anakinra treatment in patients with adult onset Still's disease and effect on clinical and laboratory outcomes. <i>Front Med (Lausanne).</i> 2020;7:42. doi:10.3389/fmed.2020.00042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/32154255/pubmed" id="32154255" target="_blank">32154255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12844139">
<a name="12844139"></a>Yang B, Baughman S, Sullivan JT. Pharmacokinetics of Anakinra in Subjects With Different Levels of Renal Function. <i>Clin Pharmacol Ther</i>. 2003;74(1):85-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/12844139/pubmed" id="12844139" target="_blank">12844139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28968868">
<a name="28968868"></a>Youngstein T, Hoffmann P, Gül A, et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. <i>Rheumatology (Oxford)</i>. 2017;56(12):2102-2108. doi:10.1093/rheumatology/kex305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/28968868/pubmed" id="28968868" target="_blank">28968868</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9246 Version 259.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
